The modulation of pro-inflammatory, disease-promoting cytokines, such as TNFα, IL-1β and IL-12, using either biologics or small molecule inhibitors is crucial to controlling RA, and many trials are still in progress demonstrating this concept [14-17]. Here, TNF is linked to rheumatoid arthritis.